B cell receptor signaling in chronic lymphocytic leukemia.
Jan A. Burger,Nicholas Chiorazzi +1 more
Reads0
Chats0
TLDR
The evolution of this field is discussed, from BCR-related prognostic markers, to mechanisms of BCR activation, and targeting of B CR-associated kinases, the emerging Achilles' heel in CLL pathogenesis.About:
This article is published in Trends in Immunology.The article was published on 2013-12-01 and is currently open access. It has received 378 citations till now. The article focuses on the topics: B-cell receptor & Chronic lymphocytic leukemia.read more
Citations
More filters
Continuing medical education activity in American Journal of Hematology
Ayalew Tefferi,Morie A. Gertz +1 more
TL;DR: The author has receivedhonoraria from the following companies: Celgene, Millen-ium, Neotope, Eisai, Inc., Lilly Research Laboratories,Optum Health Education, Research to Practice, Physician’sEducation Resource, and Amgen, Inc.
Journal ArticleDOI
Chemokine unresponsiveness of chronic lymphocytic leukemia cells results from impaired endosomal recycling of Rap1 and is associated with a distinctive type of immunological anergy.
TL;DR: It is indicated that chemokine unresponsiveness in CLL lymphocytes results from failure of Arf1/phospholipase D1–mediated translocation of Rap1 to the plasma membrane for GTP loading and may be a specific feature of anergy induced by DNA Ags.
Journal ArticleDOI
Effective Combination Therapies for B-cell Lymphoma Predicted by a Virtual Disease Model
Wei Du,Rebecca Goldstein,Yanwen Jiang,Omar Aly,Leandro Cerchietti,Ari Melnick,Olivier Elemento +6 more
TL;DR: This work constructed a detailed kinetic model of the BCR signaling network, which captured the known complex cross-talk between the NFκB, ERK, and AKT pathways and multiple feedback loops and exhaustively predicted and ranked the efficacy and synergism of all possible combinatorial inhibitions of eleven currently targetable kinases in the B CR signaling network.
Journal ArticleDOI
The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells
Michele Dal Bo,Tiziana D'Agaro,Stefania Gobessi,Antonella Zucchetto,Sara Dereani,Davide Rossi,Francesco Zaja,Gabriele Pozzato,Francesco Di Raimondo,Gianluca Gaidano,Luca Laurenti,Giovanni Del Poeta,Dimitar G. Efremov,Valter Gattei,Riccardo Bomben +14 more
TL;DR: The miR-132/SIRT1/TP53 axis was identified as a novel pathway triggered by BCR engagement that further increases the complexity of the interactions between tumor microenvironments and CLL cells.
Journal ArticleDOI
Chronic lymphocytic leukemia therapy: new targeted therapies on the way
Candida Vitale,Jan A. Burger +1 more
TL;DR: Preclinical and clinical data from phase I to III studies from promising new targeted drugs for CLL are presented in order to describe efficacy and side effect profile of these new drugs.
References
More filters
Journal ArticleDOI
Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.
Terry J. Hamblin,Zadie Davis,Zadie Davis,Anne Gardiner,Anne Gardiner,David G. Oscier,David G. Oscier,Freda K. Stevenson,Freda K. Stevenson +8 more
TL;DR: In this paper, the authors sequenced the Ig V(H) genes of the tumor cells of 84 patients with CLL and correlated their findings with clinical features, finding that the lack of somatic mutation and trisomy 12 was associated with a less favorable prognosis.
Journal ArticleDOI
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.
Rajendra N. Damle,Tarun Wasil,Tarun Wasil,Tarun Wasil,Franco Fais,Franco Fais,Franco Fais,Fabio Ghiotto,Fabio Ghiotto,Fabio Ghiotto,Angelo Valetto,Angelo Valetto,Angelo Valetto,Steven L. Allen,Steven L. Allen,Steven L. Allen,Aby Buchbinder,Aby Buchbinder,Aby Buchbinder,Daniel R. Budman,Daniel R. Budman,Daniel R. Budman,Klaus Dittmar,Klaus Dittmar,Klaus Dittmar,Jonathan E. Kolitz,Jonathan E. Kolitz,Jonathan E. Kolitz,Stuart M. Lichtman,Stuart M. Lichtman,Stuart M. Lichtman,Philip Schulman,Philip Schulman,Philip Schulman,Vincent Vinciguerra,Vincent Vinciguerra,Vincent Vinciguerra,Kanti R. Rai,Kanti R. Rai,Kanti R. Rai,Manlio Ferrarini,Manlio Ferrarini,Manlio Ferrarini,Nicholas Chiorazzi,Nicholas Chiorazzi,Nicholas Chiorazzi +45 more
TL;DR: In this paper, cellular immunophenotypic studies were performed on a cohort of randomly selected IgM(+) B-chronic lymphocytic leukemia (B-CLL) cases for which Ig V(H) and V(L) gene sequences were available.
Journal ArticleDOI
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd,Richard R. Furman,Steven Coutre,Ian W. Flinn,Jan A. Burger,Kristie A. Blum,Barbara Grant,Jeff P. Sharman,Morton Coleman,William G. Wierda,Jeffrey A. Jones,Weiqiang Zhao,Nyla A. Heerema,Amy J. Johnson,Juthamas Sukbuntherng,Betty Y. Chang,Fong Clow,Eric Hedrick,Joseph J. Buggy,Danelle F. James,Susan O'Brien +20 more
TL;DR: Ibrutinib was associated with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions.
Journal ArticleDOI
Chronic lymphocytic leukemia.
TL;DR: From the Institute for Medical Research, North Shore–LIJ Health System (N.R.R.), and the Departments of Medicine, North shore University Hospital, Manhasset, N.Y. (K.C., K.R.) and the Dipartimento di Oncologia Clinica e Sperimentale, Universitá di Genova (M.F.).
Journal ArticleDOI
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis,Vu N. Ngo,Georg Lenz,Pavel Tolar,Ryan M. Young,Paul B. Romesser,Holger Kohlhammer,Laurence Lamy,Hong Zhao,Yandan Yang,Weihong Xu,Arthur L. Shaffer,George E. Wright,Wenming Xiao,John Powell,Jian Kang Jiang,Craig J. Thomas,Andreas Rosenwald,German Ott,Hans K. Müller-Hermelink,Randy D. Gascoyne,Joseph M. Connors,Nathalie A. Johnson,Lisa M. Rimsza,Elias Campo,Elaine S. Jaffe,Wyndham H. Wilson,Jan Delabie,Erlend B. Smeland,Richard I. Fisher,Rita M. Braziel,Raymond R. Tubbs,James R. Cook,Dennis D. Weisenburger,Wing C. Chan,Susan K. Pierce,Louis M. Staudt +36 more
TL;DR: Findings establish chronic active BCR signalling as a new pathogenetic mechanism in ABC DLBCL, suggesting several therapeutic strategies.
Related Papers (5)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd,Richard R. Furman,Steven Coutre,Ian W. Flinn,Jan A. Burger,Kristie A. Blum,Barbara Grant,Jeff P. Sharman,Morton Coleman,William G. Wierda,Jeffrey A. Jones,Weiqiang Zhao,Nyla A. Heerema,Amy J. Johnson,Juthamas Sukbuntherng,Betty Y. Chang,Fong Clow,Eric Hedrick,Joseph J. Buggy,Danelle F. James,Susan O'Brien +20 more
Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.
Richard R. Furman,Jeff P. Sharman,Steven Coutre,Bruce D. Cheson,John M. Pagel,Peter Hillmen,Jacqueline C. Barrientos,Andrew D. Zelenetz,Thomas J. Kipps,Ian W. Flinn,Paolo Ghia,Herbert Eradat,Thomas J. Ervin,Nicole Lamanna,Bertrand Coiffier,Andrew R. Pettitt,Shuo Ma,Stephan Stilgenbauer,Paula Cramer,Maria Aiello,Dave Johnson,Langdon L. Miller,Daniel Li,Thomas Jahn,Roger Dansey,Michael Hallek,Susan O'Brien +26 more
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
John C. Byrd,Jennifer R. Brown,Susan O'Brien,Jacqueline C. Barrientos,Neil E. Kay,Nishitha Reddy,Steven Coutre,Constantine S. Tam,Stephen P. Mulligan,Ulrich Jaeger,S Devereux,Paul M. Barr,Richard R. Furman,Thomas J. Kipps,Florence Cymbalista,Christopher Pocock,Patrick Thornton,Federico Caligaris-Cappio,Tadeusz Robak,Julio Delgado,Stephen J. Schuster,Marco Montillo,Anna Schuh,S. de Vos,Devinder Gill,Adrian Bloor,Claire Dearden,Carol Moreno,Jeffrey Jones,Alvina D. Chu,Maria Fardis,Jesse McGreivy,Fong Clow,Danelle F. James,Peter Hillmen +34 more